期刊
CELLS
卷 11, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/cells11182830
关键词
leukemia; DOT1L; epigenetics; chromatin accessibility
类别
资金
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2017-05927]
- CancerCare Manitoba Foundation [761020451]
- Canadian Institutes of Health Research [PJT-175226]
- Graduate Enhancement of Tri-Council Stipends (GETS) through the University of Manitoba
This study investigated the broad distribution of the H3K79me2 associated with cancer, highlighting the importance of this binding feature in the diagnosis and treatment of leukemia.
A subset of expressed genes is associated with a broad H3K4me3 (histone H3 trimethylated at lysine 4) domain that extends throughout the gene body. Genes marked in this way in normal cells are involved in cell-identity and tumor-suppressor activities, whereas in cancer cells, genes driving the cancer phenotype (oncogenes) have this feature. Other histone modifications associated with expressed genes that display a broad domain have been less studied. Here, we identified genes with the broadest H3K79me2 (histone H3 dimethylated at lysine 79) domain in human leukemic cell lines representing different forms of leukemia. Taking a bioinformatic approach, we provide evidence that genes with the broadest H3K79me2 domain have known roles in leukemia (e.g., JMJD1C). In the mixed-lineage leukemia cell line MOLM-13, the HOXA9 gene is in a 100 kb broad H3K79me2 domain with other HOXA protein-coding and oncogenic long non-coding RNA genes. The genes in this domain contribute to leukemia. This broad H3K79me2 domain has an unstable chromatin structure, as was evident by enhanced chromatin accessibility throughout. Together, we provide evidence that identification of genes with the broadest H3K79me2 domain will aid in generating a panel of genes in the diagnosis and therapeutic treatment of leukemia in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据